Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Evans Blue Free Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB known ✓ | P10828 | 6/20 | 0.77 |
| ▸ | ENPP2 | Q13822 | 3/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 2/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 2/20 | 1.00 |
| ▸ | TST | Q16762 | 2/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 2/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.77 |
| ▸ | RECQL | P46063 | 5/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.77 |
| ▸ | HPGD | P15428 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.77 |
| ▸ | APEX1 | P27695 | 2/20 | 0.77 |
| ▸ | USP2 | O75604 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Evans Blue Free Acid SCHEMBL103701 | 1.00 | ENPP2 (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Evans Blue Free Acid SCHEMBL29377040 | 1.00 | ENPP2 (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Evans Blue Free Acid SCHEMBL30392230 | 1.00 | ENPP2 (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Evans Blue Free Acid SCHEMBL29381789 | 1.00 | ENPP2 (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Evans Blue Free Acid SCHEMBL2437648 | 1.00 | ENPP2 (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Evans Blue Free Acid SCHEMBL29609615 | 0.87 | MEN1 (0.98) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Chicago Sky Blue SCHEMBL93506 | 0.87 | THRB (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Chicago Sky Blue SCHEMBL29358365 | 0.87 | THRB (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Chicago Sky Blue SCHEMBL29401288 | 0.87 | THRB (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 | |
| Chicago Sky Blue SCHEMBL30201536 | 0.87 | THRB (1.00) | ENPP2HSPD1HSPE1TSTPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116982597-A | Clear light intervention system for preventing and treating acute lung injury caused by acute hypoxia | 中国人民解放军陆军军医大学 | 2023-11-03 | — | — | CN | claimed |
| EP-4499145-A1 | TRANSIENT DISRUPTION OF THE NEUROVASCULAR BARRIER OF A HUMAN AND USES THEREOF FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | SORBONNE UNIVERSITE (FR) | 2025-02-05 | — | — | EP | disclosed |
| CN-118924758-A | Use of BTK inhibitors and single dose medicaments | 武汉人福创新药物研发中心有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-118924759-A | Composition containing BTK inhibitor and application thereof | 武汉人福创新药物研发中心有限公司 | 2024-11-12 | — | — | CN | disclosed |
| CN-117100857-B | Antibody gold nano-cage medicine carrying system, preparation method and application | 福建医科大学附属协和医院 | 2024-09-10 | — | — | CN | disclosed |
| CN-118490800-B | Pharmaceutical composition for clearing heat and relieving itching as well as preparation and application thereof | 云南中医药大学 | 2024-09-06 | — | — | CN | disclosed |
| CN-118490800-A | Pharmaceutical composition for clearing heat and relieving itching as well as preparation and application thereof | 云南中医药大学 | 2024-08-16 | — | — | CN | disclosed |
| EP-4387565-A1 | COMBINATORIAL THERAPIES INCLUDING IMPLANTABLE DAMPING DEVICES AND THERAPEUTIC AGENTS FOR TREATING A CONDITION AND ASSOCIATED SYSTEMS AND METHODS OF USE | The Brain Protection Company Pty Ltd (AU) | 2024-06-26 | — | — | EP | disclosed |
| CN-117309534-A | Fungus fluorescent staining solution and preparation method and application thereof | 深圳玖明医疗科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-112391358-B | Vibrio mediterranean virulent phage vB_VmeM-Yong and application thereof | 宁波大学 | 2023-12-01 | — | — | CN | disclosed |
| CN-117100857-A | Antibody gold nano-cage medicine carrying system, preparation method and application | 福建医科大学附属协和医院 | 2023-11-24 | — | — | CN | disclosed |
| WO-2023179866-A1 | TRANSIENT DISRUPTION OF THE NEUROVASCULAR BARRIER OF A HUMAN AND USES THEREOF FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS | SORBONNE UNIVERSITE (FR) | 2023-09-28 | — | — | WO | disclosed |
| CN-115838393-B | Intermediate for FAPI synthesis and preparation method and application thereof | 烟台蓝纳成生物技术有限公司 | 2023-05-05 | — | — | CN | disclosed |
| WO-2023019320-A1 | COMBINATORIAL THERAPIES INCLUDING IMPLANTABLE DAMPING DEVICES AND THERAPEUTIC AGENTS FOR TREATING A CONDITION AND ASSOCIATED SYSTEMS AND METHODS OF USE | CARNEGIE VENTURE CAPITAL PTY LTD (AU) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022144927-A1 | A METHOD OF PREPARATION OF PURE PHARMACEUTICAL COMPOUNDS AND PHARMACEUTICAL FORMULATION THEREOF | KAR, SANTOSH KUMAR (IN) | 2022-07-07 | — | — | WO | disclosed |
| EP-3996502-A1 | COMPOSITIONS AND METHODS FOR PRESERVING ORGAN TRANSPLANTS | Firststring Research, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |